Drug hypersensitivity in HIV

Current Opinion in Allergy and Clinical Immunology

Volumn 7, Issue 4, 2007, Pages 324-330

  Phillips, Elizabeth ^a   Mallal, Simon ^b  

^a MURDOCH UNIVERSITY   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Antiretroviral therapy; Drug hypersensitivity; HIV; Major histocompatibility complex; Pharmacogenetics

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR PHOSPHATE; ATAZANAVIR; COTRIMOXAZOLE; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; HLA B ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INDINAVIR; KIVERA; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; TRAVUDA; UNCLASSIFIED DRUG;

CLINICAL FEATURE; CLINICAL TRIAL; DEVELOPING COUNTRY; DISEASE PREDISPOSITION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; EPIDEMIOLOGICAL DATA; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC VARIABILITY; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PATHOPHYSIOLOGY; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HLA-B ANTIGENS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 34447323848     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32825ea68a     Document Type: Review

References (73)

1. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993; 23:1670-1674.
2. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
3. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827-843. Updated adult guidelines for when to start treatment and with what drugs.
4. Jaffe HS, Abrams DI, Ammann AJ, et al. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet 1983; 2:1109-1111.
5. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100:495-499.
6. Winston DJ, Lau WK, Gale RP, Young LS. Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med 1980; 92:762-769.
7. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984; 100: 663-671.
8. Lin D, Tucker MJ, Rieder MJ. Increased adverse reactions to antimicrobials and anticonvulsants in patients with HIV infection. Ann Pharmacother 2006; 40:1594-1601.
9. Shear NH, Spielberg SP, Grant DM, et al. Differences in metabolism of sulfamonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105:179-184.
10. Naisbitt DJ, Hough SJ, Gill HJ, et al. Cellular disposition of sulfamethoxazole and its metabolites: implications for hypersensitivity. Br J Pharmacol 1999;126:1393-1401.
11. Lee BL, Wong D, Benowitz NL, Sullam PM. Altered patterns of drug-metabolism in patients with acquired immunodeficiency syndrome. Clin Pharm Ther 1993; 53:529-535.
12. Naisbitt DJ, Vilar FJ, Stalford AC, et al. Plasma cysteine deficiency and decreased reduction of nitrososulfamethoxazole with HIV infection. AIDS Res Hum Retroviruses 2000; 16:1929-1938.
13. Walmsley SL, Winn LM, Harrison ML, et al. Oxidative stress and thio depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: toxicological and pathological implications. AIDS 1997; 11:1689-1697.
14. Cribb AE, Spielberg SP, Griffin GP. N4-hydroxylation of sulfamethoxazole by cytochrome p450 of the cytochrome p4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat liver microsomes. Drug Metab Dispos 1995; 23:406-414.
15. Rieder MJ, Krause R, Bird IA, Dekaban GA. Toxicity of sulfmonamide-reactive metabolites in HIV-infected, HTLV-infected and noninfected cells. J Aqcuir Immune Defic Syndr Hum Retrovirol 1995; 8:134-140.
16. Naisbitt DJ, Farell J, Gordon SF, et al. Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatiblity complex restricted antigen presentation. Mol Pharmacol 2002; 62:628-637.
17. Arp J, Rieder MJ, Urquhart B, et al. Hypersensitivity of HIV-1 infected cells to reactive sulfamonamide metabolites correlated to expression of the HIV-1 viral protein tat. J Pharmacol Exp Ther 2005; 314:1218-1225.
18. Akerland B, Tynell E, Bratt G, et al. N-acetylcysteine treatment and risk of toxic reactions to trimethoprim-sulphamethoxazole in primary Pneumocystis carinii prophylaxis in HIV-infected patients. J Infect 1997; 35:143-147.
19. Walmsley SL, Khorasheh S, Singer J, Djurdjev O. A randomized trial of N-acetylcysteine for prevention of trimethoprim-sulfamethoxazole hypersensitivity reaction in Pneumocystis carinii pneumonia prophylaxis (CTN 057). Canadian HIV Trials Network 057 Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:498-505.
20. Alfirevic A, Stalford AC, Vilar FJ, et al. Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. Br J Clin Pharmacol 2003; 55:158-165.
21. Sanderson JP, Naisbitt DJ, Farrell J, et al. Sulfamethoxazole and its metabolite nitroso sulfamethoxazole stimulate dendritic cell costimulatory signalling. J Immunol 2007; 178:5533-5542.
22. Leoung GS, Stanford JF, Giordano MF, et al. Trimethoprim- sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. J Infect Dis 2001; 184:992-997.
23. Lin D, Li W, Rieder M. Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history or hypersensitivity to cotrimoxazole. Cochrane Database Syst Rev 2007; (2): CD005646. Metaanalysis of three randomized controlled studies looking at desensitization versus direct rechallenge, suggesting desensitization is safer with higher long-term success.
24. Holtzer CD, Flaherty JF Jr, Coleman RL. Cross-reactivity in HIV-infected patients switched from trimethoprim-sulfamethoxaole to dapsone. Pharmacotherapy 1998; 18:831-835.
25. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167:1472-1477.
26. Nunn P, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet 1991; 337:627-630.
27. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23:1603-1614.
28. Escaut L, Lotier JY, Albengres E, et al. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS 1999; 13:1419-1420.
29. Peyrieere H, Nicolas J, Siffert M, et al. Hypersensitivity related to abacavir in two members of family. Ann Pharmacther 2001; 35:1291-1292.
30. Mallal S, Nolan D, Witt C, et al. Association between the presence of HLA-B*5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-732.
31. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359:1121-1122.
32. Martin AM, Nolan D, Gaurdieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004; 101:4180-4185.
33. Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005; 19:979-981.
34. Walsh JS, Reese MJ, Thurmond LM, et al. The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase iszymes. Chem Biol Interact 2002; 142:135-154.
35. Martin AM, Almeida CA, Nolan D, et al. Carriage of HLA-B*5701 and a haplotypic Hsp70-Hom variant is associated with a class I MHC-restricted hypersensitivity response to abacavir. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2004; San Francisco, California.
36. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some but not all populations. Pharmacogenomics 2004; 5:203-211.
37. Phillips EJ, Sullivan JR, Knowles SR, Shear NH. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 2002; 16:2223-2225.
38. Phillips E, Rauch A, Nolan D, et al. Pharmacogenetics and clinical characteristics of patch test confirmed patients with abacavir hypersensitivity. Rev Antivir Ther 2006; 3:57. Patch test study involving three countries demonstrating 100% correlation between patch test positivity and HLA-B*5701.
39. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three vs four drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296:769-781.
40. DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz for the treatment of antiretroviral naive HIV-infected adults. Clin Infect Dis 2004; 39:1038-1046.
41. Hernandez J, Cutrell A, Bonny T, et al. Diagnosis of abacavir hypersensitivity reactions among patients not receiving abacavir in two blinded studies. Antivir Ther 2003; 8:L88.
42. Phillips EJ. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Clin Infect Dis 2006; 43:103-105. Editorial review discussing the evidence and challenges for implementing HLA-B*5701 screening into clinical practice.
43. Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43:99-102. First prospective open screening study demonstrating a reduction in both true and false positive abacavir hypersensitivity with introduction of HLA-B*5701 screening.
44. Reeves I, Churchill D, Fisher M, et al. Screening for HLA-B5701 reduces the frequency of abacavir hypersensitivity reactions. Antiviral therapy 2006; 11:L11 (abstr. no. 14).
45. Zucman D, Truchis P, Majerhold C, et al. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV Population. J Aquir Immune Defic Syndr 2007; 45:1-3. Two-year prospective screening study in Parisian urban/suburban setting, suggesting that two-step PCR-based HLA- B*5701 screening can be costeffective in more ethnically diverse populations.
46. Martin AM, Nolan D, Mallal S. HLA-B*5701 typing by sequence specific amplification: validation and comparison with sequence based typing. Tiss Antigens 2005; 65:571-574.
47. Martin AM, Krueger R, Almeida CA, et al. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenet Genomics 2006; 16:353-357. First paper to validate B17 flow assay and suggest that flow cytometry could be a feasible screening method.
48. Barreiro P, Soriano V, Casas E, et al. Prevention of nevirapine-associated exanthema using slow-dose escalation and/or corticosteroids. AIDS 2000; 14:2153-2157.
49. Stern JO, Robinson PA, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV-infected patients. J Acquir Immun Defic Syndr 2003; 34 (Suppl 1):S21-S33.
50. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998; 20:1071-1092.
51. Wong KH, Chan KC, Lee SS. Sex differences in nevirapine rash. Clin Infect Dis 2001; 33:2096-2098.
52. Patel SM, Johnson S, Belknap SM, et al. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr 2004; 35:120-125.
53. Shenton JM, Popvoc M, Chen J, et al. Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat. Chem Res Toxicol 2005; 18:1799-1813.
54. Drummond NS, Vilar FJ, Naisbitt DJ, et al. Drug-specific T cells in an HIV-positive patient with nevirapine-induced hepatitis. Antivir Ther 2006; 11:393-395.
55. Martin A, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4+ T cell counts. AIDS 2005; 19:97-99.
56. Littera R, Carcassi C, Masala A, et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 2006; 20:1621-1626. First paper to suggest that MHC class I alleles could be important in an ethnically diverse subset of patients with nevirapine hypersensitivity.
57. Gatnaga H, Yazaki H, Tanuma J, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007; 21:264-265. Short report suggesting an association between HLA-Cw8 and nevirapine hypersensitivity in Japanese patients independent of HLA-B alleles.
58. Liechty C, Solberg P, Mwima G, et al. Nevirapine-induced Stevens-Johnson syndrome in a mother and son. AIDS 2005; 19:993-994.
59. Adkins JC, Noble S. Efavirenz. Drugs 1998; 56:1055-1065.
60. Soriano V, Dona C, Barreiro P, Gonzalez-Lahoz J. Is there cross-reactivity between nevirapine and efavirenz in subjects developing rash? AIDS 2000; 14:1672-1673.
61. Gangar M, Arias G, O'Brien JG, Kemper CA. Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine. Ann Pharmacother 2000; 34:839-842.
62. Ananworanich J, Moor Z, Siangphoe U, et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS 2005; 19:185-192.
63. Manosuthi W, Thongyen S, Chumpathat N, et al. Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash. HIV Med 2006; 7:378-392. Retrospective cohort study in a Thai population suggesting low rates of clinical cross reactivity between nevirapine and efavirenz.
64. Pozniak A, Morales-Ramirez J, Mohapi L, et al. 48-week primary analysis of trial TMC278-C204:TMC278 demonstrates potent and sustained efficacy in ART-naive patients. Paper presented at the 14th CROI; 25-28 February 2007; Los Angeles, California. Abstract 144LB.
65. Chapman TM, Plosker GL, Perry CM. Fosamprenavir: a review of its use in the management of antiretroviral therapy-naïve patients with HIV infection. Drugs 2004; 64:2101-2124.
66. Phillips EJ, Knowles SR. Sulfonamide cross-reactivity: fact or fiction. Ann Pharmacother 2005; 39:1372-1373.
67. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomized trials. Lancet 2007; 369:1169-1178.
68. Lalezar J, Henry K, O'Hearn M, et al. Enfuvurtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2004; 350:1023-1035.
69. Maggi P, Ladisa N, Cinori E, et al. Cutaneous injection site reactions to long-term therapy with enfuvirtide. J Antimicrob Chemother 2004; 53:673-681.
70. Beilke MA. Acute hypersensitivity reaction to enfuvurtide upon rechallenge. Scand J Infect Dis 2004; 36:778.
71. Shahar E, Moar C, Pollack S. Successful desensitization of enfuvirtide-induced skin hypersensitivity reaction. AIDS 2005; 19:451-452.
72. Machado ES, Passoni LF, Sidi LC, et al. Successful desensitization of enfuvirtide after a first attempt failure. AIDS 2006; 20:2130-2131.
73. DeSimone JA, Ojha A, Pathak R, Cohn J. Successful desensitization to enfuvirtide after a hypersensitivity reaction in an HIV-1 infected man. Clin Infect Dis 2004; 39:e110-e112.